<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/44160F04-5CBF-4E8E-A6C6-C0EF61A5865C"><gtr:id>44160F04-5CBF-4E8E-A6C6-C0EF61A5865C</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:department>Mathematics and Statistics</gtr:department><gtr:address><gtr:line1>University House</gtr:line1><gtr:line4>Lancaster</gtr:line4><gtr:line5>Lancashire</gtr:line5><gtr:postCode>LA1 4YW</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44160F04-5CBF-4E8E-A6C6-C0EF61A5865C"><gtr:id>44160F04-5CBF-4E8E-A6C6-C0EF61A5865C</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>University House</gtr:line1><gtr:line4>Lancaster</gtr:line4><gtr:line5>Lancashire</gtr:line5><gtr:postCode>LA1 4YW</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/412FAD41-315B-406A-BD7F-EB875C0D8522"><gtr:id>412FAD41-315B-406A-BD7F-EB875C0D8522</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Wason</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/66D50C18-D88F-4104-9063-43B5EBCA1C1B"><gtr:id>66D50C18-D88F-4104-9063-43B5EBCA1C1B</gtr:id><gtr:firstName>Jack</gtr:firstName><gtr:surname>Bowden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F766798C-C03F-4546-B715-7AC05C12738E"><gtr:id>F766798C-C03F-4546-B715-7AC05C12738E</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:otherNames>Friedrich</gtr:otherNames><gtr:surname>Jaki</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ004979%2F1"><gtr:id>E08B5765-BC39-46BD-9A66-F522DECBB297</gtr:id><gtr:title>Designing and analysing multi-arm multi-stage clinical trials with one or more endpoints</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J004979/1</gtr:grantReference><gtr:abstractText>In the early stages of drug development there is often uncertainty about the most promising among a set of different treatments. In order to ensure the best use of resources in such situations it is important to decide which, if any, of the treatments should be taken forward for further testing. An efficient solution to this problem are multi-arm clinical trials in which several active treatments are compared to a common control group. By comparing several treatments within one trial the sample size and duration required tends to be markedly smaller than if each treatment would have been evaluated separately. For added efficiency it is desirable to monitor the trial at a series of interim analyses in order to allow early stopping if efficacy is quickly established and similarly to eliminate ineffective treatments early. In confirmatory studies these designs are also useful as it has been shown that using two doses instead of a single dose can markedly improve the study's success probability. 

This proposal aims to develop statistical methods to investigate how these, so called multi-arm multi-stage trials, can best be designed and analysed. The work will utilize three recently finished or currently ongoing studies in three important medical areas: HIV/AIDS, leukemia and metastatic prostate cancer. The multidisciplinary research team includes experienced clinical specialists and clinical trialists for each study from the clinical trials research unit in Leeds, the University of Liverpool and the MRC clinical trials unit as well as statisticians with experience in statistical methods for clinical trials from the University of Bremen and the Warwick medical school.</gtr:abstractText><gtr:technicalSummary>Multi-arm multi-stage designs are a broad class of designs in which several active treatment arms are compared to a common control. Their advantage over traditional 2-armed studies is that, on the one hand, a common control group is used yielding smaller expected sample sizes compared to multiple 2-armed trials and allowing direct comparisons of all active arms under the same study conditions and, on the other hand, that decisions about effective and ineffective treatments can be made at early interim analyses. Although some work on designing these trials in simple situations (e.g. play-the-winner designs) is available no adequate methods are available for many situations of practical interest (e.g. multiple endpoints). Moreover methods for adequately estimating the treatment effect and finding the corresponding confidence intervals in such trials are not available beyond two stages.

This proposal aims to 
1. develop statistical designs for multi-arm multi-stage designs that use intermediate endpoints for treatment selection; 
2. develop and evaluate methods for estimating the treatment effect and corresponding confidence intervals in multi-arm multi-stage designs with treatment selection and obtain their confidence intervals; 
3. develop statistical methods for multi-arm multi-stage designs with multiple endpoints; 
4. develop an open-source software package and associated training tailored to clinical trialists and applied statisticians working on clinical trials.</gtr:technicalSummary><gtr:potentialImpactText>In addition to academic beneficiaries, the work proposed in this grant will have great impact on others. By extending methodology for multi-arm multi-stage clinical trials (MAMS) to allow for differing endpoints at each stage, we shall be able to apply the theory of optimal design to a broader range of MAMS trials. This is of great benefit to patients recruited to such trials - stopping boundaries can be specified that reduce the average number of patients recruited to poor treatments, but keep effective treatments in the trial. Use of such designs will mean fewer patients are exposed to poor treatments. This will also be of interest to clinicians running and supporting the trial, who are naturally interested in ensuring their patients do not receive ineffective treatments. Funders of trials would also benefit, since fewer patients would be required on average, thus reducing the average cost. Because MAMS trials are high cost trials, even relatively small improvements in the design can lead to large savings in costs. Since this is a design issue, the benefit from this work will come in the medium-term future, when actual trials using the methodology start recruiting. In addition to the immediate benefit to patients on the trial the number of patients in the trial and hence the duration of the trial is reduced resulting in effective treatments to be put into clinical practice sooner.

Reducing bias in the estimation of treatment effects after a MAMS trial will be of great interest to those using results from a clinical trial. Those planning future trials will be able to use results to inform the design of their trial with the knowledge that the bias is minimised. Regulatory organisations such as the European Medicines Agency or the National Institute for Clinical Excellence will be able to judge the cost-effectiveness of a drug using reliable data. This area of research will have a more immediate impact since it can be applied to data from a MAMS trial designed prior to this work.

Through the extension of methodology to the exact and optimal design of MAMS trials with multiple endpoints, we shall make a greater range of efficient trials possible. This would be of interest to organisations that design and run trials, such as clinical trial units (CTUs) and pharmaceutical companies, or those who support the design of trials, such as research design services (RDSs). In addition, patients recruited to such trials will benefit because there will be clear, statistically sound, rules as to when to drop a treatment which is potentially dangerous. Since this is a design issue, the impact of this work would be in the medium-term future.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>443152</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biostatistics</gtr:department><gtr:description>NWHTMR</gtr:description><gtr:id>03DCDDFD-FF4A-47A1-B51B-E4EBE54BEEDA</gtr:id><gtr:impact>Joint papers, funding applications</gtr:impact><gtr:outcomeId>54496bff7f7130.77294237-1</gtr:outcomeId><gtr:partnerContribution>Joint research and implementation of methods</gtr:partnerContribution><gtr:piContribution>Joint research and support in implementation of methods</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Centre for Medical Statistics, Informatics and Intelligent Systems</gtr:department><gtr:description>Adaptive designs MUW</gtr:description><gtr:id>28A203D4-B985-4E96-BEEE-9576F3D3B079</gtr:id><gtr:impact>Publications.</gtr:impact><gtr:outcomeId>BYhg8A6w17j-1</gtr:outcomeId><gtr:partnerContribution>Joint research</gtr:partnerContribution><gtr:piContribution>Joint research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>SCT Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2CDCDAEC-E487-490B-A4F7-E18DEBAF652A</gtr:id><gtr:impact>Invited Conference talk at the Society for Clinical Trials conference</gtr:impact><gtr:outcomeId>56b5ff94700da2.28336620</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>8th International Conference on Multiple Comparison Procedures, Southampton, UK, Sept 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3162D11C-7172-42CE-97B8-DECE1479ED52</gtr:id><gtr:impact>Invited presentation at 8th International Conference on Multiple Comparison Procedures, Southampton, UK, Sept 2013</gtr:impact><gtr:outcomeId>56b600e8abdc11.90460014</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Adaptive and Bayesian Methods Course</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B3DBDC69-4787-4370-9D59-7BE80232B211</gtr:id><gtr:impact>Short course on adaptive and Bayesian methods</gtr:impact><gtr:outcomeId>56b5ff1dd7f652.66789804</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Biometric Conference, Florence, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2539573F-E2A5-4756-9D67-AE5A1BF61F74</gtr:id><gtr:impact>Invited conference presentation at International Biometric Conference</gtr:impact><gtr:outcomeId>56b60008081d38.70422891</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI CTU annual meeting 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>81BBCDF1-441A-4CC4-847E-B23E4855CF49</gtr:id><gtr:impact>Workshop on &amp;quot;Novel trial designs for phase II oncology&amp;quot; at NCRI CTU annual meeting 2015</gtr:impact><gtr:outcomeId>56bcbd65633ec3.75963381</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference of the Austro-Swiss Region of the International Biometric Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>46288060-0EAC-4CEF-8556-425C5313D3DF</gtr:id><gtr:impact>Invited presentation at Conference of the Austro-Swiss Region of the International Biometric Society</gtr:impact><gtr:outcomeId>56b600a5859c05.98998653</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Conference on Simultaneous Inference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A08EBCB-6494-45AF-8DDB-116AC6D1EDD3</gtr:id><gtr:impact>Invited presentation at International Conference on Simultaneous Inference</gtr:impact><gtr:outcomeId>56b600535e2db1.96734139</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Design of Experiments in Drug Development open for business</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>577F1954-5C94-4D80-835C-171FFB4A9708</gtr:id><gtr:impact>Discussion event around improving drug development through adaptive designs.</gtr:impact><gtr:outcomeId>56b60269914194.51216198</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Statistical Innovations in Clinical Trials Workshop 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07AAE3D5-4FA5-446D-9D0B-6D46E3C8F528</gtr:id><gtr:impact>Workshop on Statistical Innovations in Clinical Trials Workshop 2015 by PSI</gtr:impact><gtr:outcomeId>56bcbd00ad5d60.26448402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.psiweb.org/events/event-item/2015/06/29/default-calendar/one-day-meeting---adaptive-designs-workshop-at-amgen-(uxbridge)</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Short courses</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8DF1D74F-5665-44AC-B62D-06EF740F9142</gtr:id><gtr:impact>Several short-course for professionals and students that are based on the undertaken research

Wider uptake of methods</gtr:impact><gtr:outcomeId>544973018ac812.19990976</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>345000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Methodology Research Panel - Estimation project</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M005755/1</gtr:fundingRef><gtr:id>0B100090-CA37-467B-96C0-A86824A6028A</gtr:id><gtr:outcomeId>5453901603b2a0.54299485</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3639394</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie ITN</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>633567</gtr:fundingRef><gtr:id>D74A159C-427E-47A6-A91F-5766DFC3CEAE</gtr:id><gtr:outcomeId>54538f791bd978.28276474</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>653526</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Senior Research Fellowship</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>SRF-2015-08-001</gtr:fundingRef><gtr:id>E0E202F3-AD58-4952-AD06-B63ADEDC7660</gtr:id><gtr:outcomeId>56b5e7ba9df650.18494773</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Short-course Oxford</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4A6B5B5C-9757-4DD5-AA67-5DF13934B91F</gtr:id><gtr:impact>Improved understanding of available tools for more efficient clinical trials</gtr:impact><gtr:outcomeId>5460e493c7fe88.68440426</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Software to design multi-arm multi-stage designs in the statistical software R</gtr:description><gtr:id>8F9EA28B-61D2-4BE9-8C1F-768760997C70</gtr:id><gtr:impact>Increased uptake of the methodology</gtr:impact><gtr:outcomeId>5449705c6689f8.11019009</gtr:outcomeId><gtr:title>MAMS package</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://cran.r-project.org/web/packages/MAMS/index.html</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>496A51D8-2DE1-42D6-BDD9-E1CFAA642EDB</gtr:id><gtr:title>Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56b5e0f25a7a66.86529032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56DED8D7-F410-4389-8A32-313D20DD7BB0</gtr:id><gtr:title>Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>56bcbbe8a1ece2.63468533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>339ED0CC-E421-4AE1-80AC-15AC99A4ADBA</gtr:id><gtr:title>Adaptive clinical trials in tuberculosis: applications, challenges and solutions.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0bd9d624f992d94fa7c0f219fb2903"><gtr:id>fd0bd9d624f992d94fa7c0f219fb2903</gtr:id><gtr:otherNames>Davies GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5675e3e0bc9aa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BA38BCF-A15E-466B-8F65-4D746B94A255</gtr:id><gtr:title>Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>5a678d837c65c1.71941137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59CDB15E-AAC9-4354-8D82-F82850183BEF</gtr:id><gtr:title>Identifying combined design and analysis procedures in two-stage trials with a binary end point.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>doi_22859_2_sim_5468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>254853F2-6E52-40A8-B0AF-B97EE1DBE10E</gtr:id><gtr:title>Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.</gtr:title><gtr:parentPublicationTitle>Statistical science : a review journal of the Institute of Mathematical Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0883-4237</gtr:issn><gtr:outcomeId>5675f5b74a04a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>381080AD-6639-4502-8A30-B1C74818DEAB</gtr:id><gtr:title>Planning multi-arm screening studies within the context of a drug development program.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>doi_22859_2_sim_5787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90AFA7E1-8054-439E-8CAC-65516A41938A</gtr:id><gtr:title>Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>doi_22859_6215_14_23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF8E5648-2A4D-4CAD-91CA-AACAA109ABE6</gtr:id><gtr:title>Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56b5e208de5b84.94869987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75637F4A-3475-44B7-BB41-5E3C4C23F255</gtr:id><gtr:title>Some recommendations for multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>pm_22859_29_23242385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>027877A2-D670-44AD-BBD8-290120D965F1</gtr:id><gtr:title>A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical and biomedical analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0731-7085</gtr:issn><gtr:outcomeId>58a2e2ac689555.55745593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1762BEA-B7C8-4970-AAE5-5B4E84D778F1</gtr:id><gtr:title>A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544aae06832a73.70834307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>798FB530-D815-482D-BC21-0A3848EAA3ED</gtr:id><gtr:title>Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>doi_22859_2_sim_5920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B950C2E6-D3F8-4CDC-AB5A-BEDC26F140EA</gtr:id><gtr:title>Flexible sequential designs for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544967aad81ee6.50100404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23F29643-C131-4C2F-91C2-4B6BA2E8FF74</gtr:id><gtr:title>A multi-stage drop-the-losers design for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544aacc0469915.63930116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E785D2E-804A-458E-89EA-A6B049ED8483</gtr:id><gtr:title>A Bayesian adaptive design for biomarker trials with linked treatments.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56bcbb9e906d43.31087922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC56BE8E-927A-4085-A287-168998AB5DD4</gtr:id><gtr:title>Optimal design of multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_22859_29_22826199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E0D9FFC-0E1B-46A5-AE51-3077EEC670D6</gtr:id><gtr:title>Multi-arm clinical trials with treatment selection: what can be gained and at what price?</gtr:title><gtr:parentPublicationTitle>Clinical Investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>54cbe6d8865519.33561524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39CC0E67-611D-471F-8084-5993975BCA1F</gtr:id><gtr:title>Design issues in multi-stage drop-the-losers trials</gtr:title><gtr:parentPublicationTitle>Statistical Methods in Medical Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>GrTUgn79RzL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>699B93FE-377E-4D47-BA27-2383BE07115A</gtr:id><gtr:title>Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.</gtr:title><gtr:parentPublicationTitle>Biometrical journal. Biometrische Zeitschrift</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0323-3847</gtr:issn><gtr:outcomeId>pm_540e192e192b02e80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CBFF1D6-3AEA-449A-9B92-16221BD570B3</gtr:id><gtr:title>Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58a1baed002bc1.25404808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>312CB50C-5714-4C71-A32F-BAA7A3FB3153</gtr:id><gtr:title>Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>544aad73b49987.62903539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D36952EA-27B4-432B-B7C7-694C3FF0A043</gtr:id><gtr:title>Simultaneous confidence intervals that are compatible with closed testing in adaptive designs.</gtr:title><gtr:parentPublicationTitle>Biometrika</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3444</gtr:issn><gtr:outcomeId>54496862d05837.56790400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5402EBA-8A3C-4F55-877F-806054D2D682</gtr:id><gtr:title>Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56b5ddc9e3a477.72257038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59F089DE-31C0-46F8-B598-13265F20BFA9</gtr:id><gtr:title>Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_22859_29_23112135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6548A6E6-9ADE-4EE6-92AE-D5B2FA628C79</gtr:id><gtr:title>A review of statistical designs for improving the efficiency of phase II studies in oncology.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544aac5ab9ecd7.70576237</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J004979/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>